Published by
@ShahidNShah
@ShahidNShah
0-50Healthcare
65 rue de Prony, Paris, 75017, France
Iktos was founded in 2016 by Quentin Perron, Nicolas Do Huu, and Yann Gaston-Mathé, with the aim of developing an innovative and user-friendly technology platform for deep learning-based de novo drug design, leveraging a proprietary algorithm developed by Quentin and Nicolas. This proprietary technology enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. Today, Iktos is a leading player in AI-based generative chemistry having delivered value in 50-plus real world research collaborations with some of the most eminent pharma companies globally.
The Iktos Makya is a novel SaaS platform that employs AI-driven de novo drug design technology that focuses on Multi-Parametric Optimization (MPO). The platform is the first of its kind, offering an …
Posted Artificial Intelligence
Last Updated
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Nov 8, 2024 at 5:56am